Vault-13

Ally Bridge Group (NY) LLC

NEW YORK, NY · CIK 1822947 · 13F filing filed 2026-08-14

SEC-registered investment adviser since 2021 · limited liability company

As an employer

Where they work

people there (dot area)number not reportedmain officeHover or tap a dot. Australian and UK companies are placed at their business or registered address, with their staff across the whole country.

Offices

From Form ADV: the main office and the other offices where it does advisory work (at most the 25 largest), with the people doing investment work at each. “About” is worked out: the firm's investment staff less its other offices. Each city links to the other managers there.

CityCountryPeople
New York, NY (main office)United States United Statesabout 3
Miami, FLUnited States United States1

Map: places from GeoNames (CC BY 4.0), outlines from Natural Earth.

$77.6m reported value -22.9% vs Q1 2026
23positions
64.8%in top 10
10 new 2 added 9 reduced 8 sold out vs Q1 2026

Options: 2 call positions ($35.5m notional), 0 put positions (— notional) – listed below, not included above.

This report includes the holdings of 1 other manager that shares the investment decisions:

Shares in two reports are counted once in each security's totals.

Holdings, Q2 2026

The small lines show how much was held over the last 4 quarters (adjusted for stock splits).

#SecurityTickerShares Value% of portfolioChangeShares change
1 MINERVA NEUROSCIENCES INC COM NEW NERV NERV 2,175,802 $12.1m15.56% 15.56% AddedShares held: Q3 2025 0, Q4 2025 1.7m, Q1 2026 1.7m, Q2 2026 2.2m +520.3k +520,302 31.4%
2 PROMIS NEUROSCIENCES INC COM SHS PMN PMN 620,319 $8.2m10.52% 10.52% AddedShares held: Q3 2025 0, Q4 2025 249.3k, Q1 2026 414.2k, Q2 2026 620.3k +206.1k +206,100 49.8%
3 FIRST TRACKS BIOTHERAPEUTICS ORD SHS TRAX TRAX 284,287 $5.7m7.37% 7.37% NewShares held: Q3 2025 0, Q4 2025 0, Q1 2026 0, Q2 2026 284.3k
4 AXSOME THERAPEUTICS INC COM AXSM AXSM 16,493 $4.0m5.20% 5.20% NewShares held: Q3 2025 0, Q4 2025 0, Q1 2026 0, Q2 2026 16.5k
5 ASSEMBLY BIOSCIENCES INC COM NEW ASMB ASMB 140,000 $3.8m4.96% 4.96% NewShares held: Q3 2025 0, Q4 2025 0, Q1 2026 0, Q2 2026 140.0k
6 AADI BIOSCIENCE INC COM WHWK WHWK 817,939 $3.7m4.83% 4.83% UnchangedShares held: Q3 2025 817.9k, Q4 2025 817.9k, Q1 2026 817.9k, Q2 2026 817.9k
7 EDGEWISE THERAPEUTICS INC COM EWTX EWTX 83,300 $3.4m4.36% 4.36% ReducedShares held: Q3 2025 0, Q4 2025 195.0k, Q1 2026 161.0k, Q2 2026 83.3k -77.7k -77,700 -48.3%
8 CLIMB BIO INC COM CLYM CLYM 249,172 $3.2m4.19% 4.19% NewShares held: Q3 2025 0, Q4 2025 0, Q1 2026 0, Q2 2026 249.2k
9 KURA ONCOLOGY INC COM KURA KURA 290,000 $3.2m4.10% 4.10% NewShares held: Q3 2025 0, Q4 2025 0, Q1 2026 0, Q2 2026 290.0k
10 CYTOMX THERAPEUTICS INC COM CTMX CTMX 775,000 $2.9m3.75% 3.75% ReducedShares held: Q3 2025 0, Q4 2025 0, Q1 2026 900.0k, Q2 2026 775.0k -125.0k -125,000 -13.9%
11 AVALO THERAPEUTICS INC COM NEW AVTX AVTX 150,000 $2.8m3.57% 3.57% NewShares held: Q3 2025 178.1k, Q4 2025 0, Q1 2026 0, Q2 2026 150.0k
12 PALISADE BIO INC COM PALI PALI 1,229,000 $2.6m3.31% 3.31% NewShares held: Q3 2025 0, Q4 2025 0, Q1 2026 0, Q2 2026 1.2m
13 SOLID BIOSCIENCES INC COM NEW SLDB SLDB 255,959 $2.6m3.30% 3.30% ReducedShares held: Q3 2025 549.2k, Q4 2025 413.6k, Q1 2026 767.0k, Q2 2026 256.0k -511.0k -511,015 -66.6%
14 AN2 THERAPEUTICS INC COM ANTX ANTX 526,315 $2.5m3.28% 3.28% UnchangedShares held: Q3 2025 0, Q4 2025 0, Q1 2026 526.3k, Q2 2026 526.3k
15 UROGEN PHARMA LTD COM URGN URGN 69,183 $2.5m3.28% 3.28% ReducedShares held: Q3 2025 0, Q4 2025 0, Q1 2026 202.1k, Q2 2026 69.2k -132.9k -132,941 -65.8%
16 PERSPECTIVE THERAPEUTICS INC COM NEW CATX CATX 743,958 $2.5m3.27% 3.27% ReducedShares held: Q3 2025 0, Q4 2025 0, Q1 2026 926.6k, Q2 2026 744.0k -182.6k -182,599 -19.7%
17 IDEAYA BIOSCIENCES INC COM IDYA IDYA 67,500 $2.5m3.24% 3.24% NewShares held: Q3 2025 0, Q4 2025 0, Q1 2026 0, Q2 2026 67.5k
18 INVENTIVA SA ADS IVA IVA 634,800 $2.4m3.09% 3.09% ReducedShares held: Q3 2025 0, Q4 2025 1.5m, Q1 2026 745.3k, Q2 2026 634.8k -110.5k -110,500 -14.8%
19 ALUMIS INC COM ALMS ALMS 76,459 $2.2m2.77% 2.77% ReducedShares held: Q3 2025 0, Q4 2025 0, Q1 2026 167.0k, Q2 2026 76.5k -90.5k -90,500 -54.2%
20 OVID THERAPEUTICS INC COM OVID OVID 624,561 $1.7m2.17% 2.17% ReducedShares held: Q3 2025 0, Q4 2025 1.8m, Q1 2026 2.8m, Q2 2026 624.6k -2.2m -2,193,898 -77.8%
21 EUPRAXIA PHARMACEUTICALS INC COM EPRX EPRX 252,175 $1.7m2.15% 2.15% ReducedShares held: Q3 2025 915.0k, Q4 2025 397.9k, Q1 2026 660.4k, Q2 2026 252.2k -408.2k -408,200 -61.8%
22 IBIO INC COM NEW IBIO IBIO 390,147 $682.8k0.88% 0.88% NewShares held: Q3 2025 0, Q4 2025 0, Q1 2026 0, Q2 2026 390.1k
23 TRAWS PHARMA INC COM NEW TRAW TRAW 786,236 $663.0k0.85% 0.85% NewShares held: Q3 2025 0, Q4 2025 0, Q1 2026 0, Q2 2026 786.2k

Sold out since Q1 2026

SecurityTickerShares held beforeValue then
PRAXIS PRECISION MEDICINES I PRAX PRAX 32,810 $10.6m32.8k shares
SOLENO THERAPEUTICS INC SLNO SLNO 200,000 $6.7m200.0k shares
COMPASS PATHWAYS PLC CMPS CMPS 1,045,000 $5.8m1.0m shares
TARSUS PHARMACEUTICALS INC TARS TARS 80,859 $5.7m80.9k shares
ABIVAX SA ABVX ABVX 33,712 $3.8m33.7k shares
CAPRICOR THERAPEUTICS INC CAPR CAPR 113,899 $3.5m113.9k shares
INHIBIKASE THERAPEUTICS INC IKT IKT 1,325,000 $2.2m1.3m shares
RELMADA THERAPEUTICS INC RLMD RLMD 210,525 $1.5m210.5k shares

Options (notional value)

UnderlyingTickerTypeShares controlled NotionalChange
DEFINIUM THERAPEUTICS INC DFTX · Call DFTXCall 400,000 $18.8m400.0k shares New
ABIVAX SA ABVX · Call ABVXCall 125,000 $16.7m125.0k shares New